Kely Exports AND Imports

Kely Exports and Imports, established in 1995, is a privately held Indian company specializing in the export and import of Ayurvedic and herbal pharmaceutical formulations. The company is headquartered in Kottakkal, Malappuram District, Kerala, India. The Managing Director is Mr. Abdul Rahman, who has been instrumental in steering the company's growth and international expansion.

The company's Corporate Identification Number (CIN) is U01100KL1995PTC008999. While specific revenue figures are not publicly disclosed, Kely Exports and Imports has demonstrated a consistent growth trajectory in the pharmaceutical export sector. The company employs a dedicated team of professionals committed to delivering high-quality Ayurvedic products to global markets.

Kely Exports and Imports operates manufacturing facilities in Kottakkal, Kerala, a region renowned for its rich tradition in Ayurvedic medicine. The facilities are equipped with state-of-the-art technology to produce a range of Ayurvedic and herbal pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company emphasizes adherence to Good Manufacturing Practices (GMP) to ensure product quality and safety.

Mr. Abdul Rahman serves as the Managing Director of Kely Exports and Imports. Under his leadership, the company has expanded its footprint in international markets, particularly in the Middle East and Europe. His strategic vision and commitment to quality have been pivotal in establishing the company's reputation in the Ayurvedic pharmaceutical export sector.

Kely Exports and Imports has made significant inroads into regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and certifications to export its Ayurvedic pharmaceutical formulations to these regions. This includes compliance with the World Health Organization's Good Manufacturing Practices (WHO GMP) and European Union Good Manufacturing Practices (EU GMP), ensuring that their products meet international quality standards.

The company has also expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. By obtaining WHO prequalification, Kely Exports and Imports has enhanced its credibility and access to these regions, facilitating the distribution of its Ayurvedic pharmaceutical products. This strategic move aligns with the global trend of increasing demand for traditional medicine and herbal products.

Kely Exports and Imports has adopted a strategic approach to geographic diversification, focusing on both developed and emerging markets. While the company has a strong presence in the Middle East and Europe, it is actively exploring opportunities in Africa, Latin America, and Southeast Asia. This diversification strategy mitigates concentration risk and positions the company to capitalize on the growing global demand for Ayurvedic pharmaceutical products.

Kely Exports and Imports has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulations for pharmaceutical imports. The company has obtained the necessary approvals for its Ayurvedic pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific details regarding Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) are not publicly disclosed, the company's adherence to international quality standards indicates a commitment to regulatory compliance.

Kely Exports and Imports has achieved WHO prequalification and holds EU GMP certificates, demonstrating its commitment to maintaining high manufacturing standards. These certifications are crucial for accessing and maintaining a presence in international markets, as they assure regulatory authorities and consumers of the company's adherence to stringent quality and safety standards.

In India, Kely Exports and Imports operates under the guidelines set by the Central Drugs Standard Control Organisation (CDSCO). The company holds the necessary manufacturing licenses and approvals from state drug controllers, ensuring compliance with national regulations for pharmaceutical manufacturing and export. Additionally, the company obtains export No Objection Certificates (NOCs) as required for international trade.

As of March 2026, there have been no publicly reported regulatory actions such as Form 483 observations, warning letters, or import alerts issued against Kely Exports and Imports. This indicates a positive compliance history with regulatory authorities, reflecting the company's commitment to maintaining high standards in its manufacturing and export operations.

Kely Exports and Imports operates in a competitive landscape with several key players in the Ayurvedic pharmaceutical export sector. While specific market share data is not publicly available, the company's focus on high-quality Ayurvedic formulations and adherence to international standards positions it favorably in the market. The company's strategic diversification into emerging markets further enhances its competitive edge.

Kely Exports and Imports differentiates itself through its deep-rooted expertise in Ayurvedic medicine, commitment to quality, and adherence to international manufacturing standards. The company's focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, allows it to cater to a broad spectrum of consumer needs. Additionally, its strategic geographic diversification enables the company to tap into various markets, mitigating risks associated with market concentration.

Kely Exports and Imports is strategically positioned as a leading exporter of Ayurvedic pharmaceutical formulations. The company's focus on finished dosage forms aligns with global trends favoring ready-to-use pharmaceutical products. Looking ahead, the company aims to expand its product portfolio and strengthen its presence in both established and emerging markets, capitalizing on the growing global demand for traditional and herbal medicines.

Kely Exports and Imports has demonstrated a strong track record in the pharmaceutical export sector, with a total export value of $70,000 USD and 236 shipments across two products in the Ayurvedic and Herbal Products category. The company's portfolio is highly concentrated, with the top five products accounting for 100% of the export value. This indicates a focused approach to product offerings, which can be advantageous in maintaining quality and brand identity.

Importers should verify the following certifications when considering Kely Exports and Imports as a supplier:

• FDA Registration: Confirm that the company's manufacturing facilities are registered with the U.S. Food and Drug Administration, ensuring compliance with U.S. import regulations.

• WHO GMP Certification: Verify that the company holds World Health Organization Good Manufacturing Practices certification, indicating adherence to international quality standards.

• EU GMP Certification: Ensure that the company possesses European Union Good Manufacturing Practices certification, facilitating access to European markets.

• ISO Certification: Check for International Organization for Standardization certification, which reflects the company's commitment to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting copies directly from the company.

When conducting due diligence on Kely Exports and Imports, consider the following steps:

• Verify Regulatory Compliance: Confirm the company's certifications and licenses with relevant authorities.

• Assess Financial Stability: Review financial statements and credit reports to evaluate the company's financial health.

• Evaluate Product Quality: Request product samples and conduct quality assessments to ensure they meet your standards.

• Check References: Contact previous clients and partners to gather feedback on the company's reliability and performance.

• Inspect Manufacturing Facilities: If possible, visit the company's manufacturing sites to assess operational standards and practices.

Be vigilant for red flags such as discrepancies in certification details, negative feedback from references, or inconsistencies in financial records. Conducting thorough due diligence will help mitigate risks and establish a successful partnership.